Agomab Therapeutics share price logo

Agomab Therapeutics Share Price

NASDAQ: AGMB

Small Cap

$10.93

-0.94

(-7.92%)

as on

Agomab Therapeutics Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $10.51
    $12.00
    downward going graph

    3.84%

    Downside

    9.79%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Agomab Therapeutics share price movements today

Previous Close
$11.87
Open
$11.92
Volume
713.4K
Day's Low - High
$10.51 - $12.00

Agomab Therapeutics Historical Returns

1 Month Return
-32.27 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Agomab Therapeutics Stock Fundamentals & Key Indicators

Check Agomab Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$584.2M

EPS (TTM)

-82.325

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Agomab Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Agomab Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Agomab Therapeutics image
Agomab Therapeutics
NA$584.2MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%

Agomab Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Dec 2024
Total Revenue
-
Gross Profit
-
Operating Income
-11
EBITDA
-11
Interest Expense
0
Depreciation
0
Income Before Tax
-11
Income Tax Expense
0
Net Income
-12
Net Profit Margin
0.00%

Agomab Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
Gross Profit
-
-
-
Operating Income
-22
-31
-48
EBITDA
-10
-11
-45
Interest Expense
0
0
0
Depreciation
0
0
0
Income Before Tax
-10
-12
-46
Income Tax Expense
-2
0
0
Net Income
-8
-12
-48
Net Profit Margin
0.00%
0.00%
0.00%

Agomab Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-11
-46
Operating Cash Flow
-24
-46
Investing Cash Flow
-
-
Financing Cash Flow
79
96
Change in Cash
94
49

Insights on Agomab Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, AGMB stock has moved down by -32.3%

About Agomab Therapeutics

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
OrganisationAgomab Therapeutics
HeadquartersPosthoflei 1/6, Antwerp, Belgium, 2600
CEODr. Tim Knotnerus MSc, Ph.D.
E-voting on sharesClick here to vote

Key Management of Agomab Therapeutics

Name

Title

Dr. Tim Knotnerus MSc, Ph.D.

CEO & Executive Director

Mr. Paolo Michieli Ph.D.

Founder, Senior Advisor & Member of Scientific Advisory Board

Mr. Pierre Kemula B.Sc.

Chief Financial Officer

Sofie Van Gijsel

Vice President of Investor Relations

Ms. Ellen Lefever

General Counsel

Dr. Philippe Wiesel M.D.

Chief Medical Officer

Dr. Paul Van Der Horst Ph.D.

Chief Business Officer

Dr. Andrea Sáez Borderías Ph.D.

Chief Development Officer

FAQs

What is Agomab Therapeutics share price today?

Agomab Therapeutics share price today is $10.93 as on at the close of the market. Agomab Therapeutics share today touched a day high of $12 and a low of $10.51.

What is the 52 week high and 52 week low for Agomab Therapeutics share?

Agomab Therapeutics share touched a 52 week high of $ on and a 52 week low of $ on . Agomab Therapeutics stock price today i.e. is closed at $10.93,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Agomab Therapeutics's market capitalisation today?

Agomab Therapeutics market capitalisation is $0.00T as on .

How to invest in Agomab Therapeutics Stock (AGMB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Agomab Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agomab Therapeutics Shares that will get you 0.1372 shares as per Agomab Therapeutics share price of $10.93 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Agomab Therapeutics Stock (AGMB) from India?

Indian investors can start investing in Agomab Therapeutics (AGMB) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Agomab Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Agomab Therapeutics share’s latest price of $10.93 as on March 28, 2026 at 1:29 am IST, you will get 0.9149 shares of Agomab Therapeutics. Learn more about fractional shares .